Loading market data...

Back to Market Intelligence
IndiaEquities / IPOs

Manipal Health Faces Flat Mumbai Listing as IPO Momentum Cools

Manipal Health’s ₹9,275 crore IPO is set for a flat Mumbai debut after grey-market indications declined from an earlier premium to around the ₹590 issue price.

MSA Market Desk
Manipal Health Faces Flat Mumbai Listing as IPO Momentum Cools

MSA market desk

Desk brief

Manipal Health Enterprises is scheduled to list on India’s BSE and NSE on August 5, 2026, following a ₹9,275 crore initial public offering priced at ₹590 per share. The Temasek-backed hospital operator’s issue comprised a fresh share sale of up to ₹8,000 crore alongside an offer for sale by existing shareholders.

Unofficial market indicators weakened sharply during the final days before listing. After grey-market premiums had suggested a potential gain of roughly 9% earlier in the offering process, recent indications placed the shares around the ₹590 issue price, pointing to limited or no opening-day premium.

The subdued signal highlights more cautious investor positioning toward large, richly valued healthcare offerings, despite the sector’s structural growth prospects. Proceeds from the fresh issue are intended to support balance-sheet strengthening, acquisitions and broader corporate purposes.

Continue the desk read

Browse all
Global macro / central banksIndia

RBI set to announce August policy decision with 5.25% repo rate in focus

The RBI’s August decision is due with the repo rate at 5.25% and an economist consensus leaning toward no change. Market sensitivity should center on any unexpected hike or dovish shift, particularly through Indian bonds, the rupee and wider emerging-market policy expectations.

central-bank policyIndia

RBI decision due August 5 as markets lean toward an unchanged repo rate

The RBI’s August 5 policy decision is the next scheduled catalyst for Indian rates, the rupee and emerging-market carry sentiment. Available evidence points to a majority expectation of an unchanged repo rate, but no verified outcome or market reaction was identified in the publication window.